| Today's Top Story |  |  | | - Panel urges greater genome sequencing privacy protection
Whole genome sequencing offers enormous promise for enhancing medical care and is helping researchers identify the genetic causes of rare diseases, but it raises privacy issues, according to the report "Privacy and Progress in Whole Genome Sequencing," by the Presidential Commission for the Study of Bioethical Issues. The commission recommended creating "clear policies" on who has access to whole genome data and how it can be used, as well as informing patients of the consequences and risks of sequencing. ScienceMag.org/ScienceInsider blog (10/11), USA TODAY (10/11)       | | Health Care & Policy | | | | - Global Alzheimer's trial will study Roche, Lilly drugs
Experimental Alzheimer's drugs from Roche Holding and Eli Lilly and Co. will be studied in a global trial of 160 patients with genetic indicators that they are prone to the disease. The study, set to begin next year, will include Roche's gantenerumab and Lilly's solanezumab, and a beta-secretase inhibitor from Lilly could be added. Reuters (10/10) - Nobel goes to physicians for research on how drugs work
Dr. Robert Lefkowitz, a professor of biochemistry, pathology and medicine at Duke University Medical Center and an investigator for the Howard Hughes Medical Institute, as well as Dr. Brian Kobilka, a professor of molecular and cellular physiology and medicine at Stanford University, received the Nobel Prize in Chemistry for their work on how cells identify and react to hormones. About half of drugs work through G-protein-coupled receptors, and the Lefkowitz and Kobilka's work could lead to treatments with fewer side effects. The Christian Science Monitor (10/10) - GSK and Aeras plan multinational trial of TB vaccine
Nonprofit biotech group Aeras and GlaxoSmithKline aim to initiate next year a Phase IIb study to evaluate the efficacy of an investigational tuberculosis vaccine in India, Kenya and South Africa. The trial, subject to regulatory approval, would involve healthy adults ages 18 to 50. The vaccine is designed to be used in combination with Bacille Calmette-Guerin, an existing TB vaccine. Reuters (10/10) | Company & Financial News | | | | | Industry Deals | | | | | Food & Agriculture | | | | - Vilmorin ends plans to test biotech crops in France
Vilmorin & Cie has decided not to carry out field trials of biotech crops in France next year, but it will continue the tests in Spain and two other nations in Europe. "The political climate led us to put the question on hold for now," Vilmorin Chief Financial Officer Daniel Jacquemond said. Biotech crops "are absolutely essential components for the competitiveness of agriculture including Europe," Jacquemond said. Reuters (10/10) | Industrial & Environmental | | | | - BIO: Altering RFS would impede advanced biofuels development
Suspending the Renewable Fuel Standard would undercut the development of advanced biofuel, writes BIO president and CEO Jim Greenwood. "Rushing into long-term policy changes to the RFS could have an unintended economic impact on family farmers, biofuel producers and consumers. Additionally, waiving the RFS requirement could reduce the momentum that has been building toward producing other second-generation fuels," Greenwood writes. The Hill/Congress Blog (10/10)  | |  | | The Buzz(CORPORATE ANNOUNCEMENTS)
| |  | |  |
| News from BIO | | | | - BIOtechNOW
BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter.
| SmartQuote | | | |  | Action may not always bring happiness; but there is no happiness without action."
--Benjamin Disraeli,
British politician  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Wednesday, October 10, 2012
- Tuesday, October 09, 2012
- Monday, October 08, 2012
- Friday, October 05, 2012
- Thursday, October 04, 2012
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2012 SmartBrief, Inc.® Legal Information |
|
No comments:
Post a Comment